Vaginal News and Research

RSS

Advisory Committee on Immunization Practices supports the permissive use of GARDASIL

Merck & Co., Inc. announced today that the U.S. Centers for Disease Control and Prevention’s (CDC’s) Advisory Committee on Immunization Practices (ACIP) supports the permissive use of GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] for boys and young men ages 9 to 26, which means that GARDASIL may be given to males ages 9 to 26 to reduce the likelihood of acquiring genital warts at the discretion of the patient's health care provider.

22 Oct 2009

Interim study analysis comparing MENOPUR with rFSH in GnRH Antagonist IVF cycles

Ferring Pharmaceuticals presented an interim study analysis indicating that MENOPUR® (menotropins for injection, USP) is effective in in vitro fertilization (IVF) cycles using a gonadotropin-releasing hormone (GnRH) antagonist. The results were presented in a poster at the 65th Annual Meeting of the American Society for Reproductive Medicine (ASRM) in Atlanta, October 17-21, 2009.

21 Oct 2009

No significant differences in pregnancy outcomes with different progesterone formulations

A retrospective analysis, conducted at a large infertility clinic between January 2003 and December 2008, demonstrated that there were no significant differences in pregnancy outcomes with three different progesterone formulations for women aged 35 to 40 undergoing in vitro fertilization-embryo transfer (IVF-ET) procedures. These data were presented at the American Society for Reproductive Medicine (ASRM) annual meeting in Atlanta.

21 Oct 2009

FDA approves Gardasil vaccine usage in boys and men for preventing genital warts

The U.S. Food and Drug Administration today approved use of the vaccine Gardasil for the prevention of genital warts (condyloma acuminata) due to human papillomavirus (HPV) types 6 and 11 in boys and men, ages 9 through 26.

19 Oct 2009

NCCN updates NCCN Clinical Practice Guidelines in Oncology for Cervical Cancer Screening

The National Comprehensive Cancer Network (NCCN) recently made updates to the NCCN Clinical Practice Guidelines in Oncology(TM) for Cervical Cancer Screening that include a new section providing recommendations for women who have positive results for the HPV High Risk DNA test but negative cervical cytology screen/Pap smears.

15 Oct 2009

Overview of procedures and techniques used for embryo transfer under transvaginal ultrasound guidance

Fertility and reproductive specialists are invited to join a live, online chat event entitled, “Transvaginal Ultrasound Transfers” at www.CookARTLab.com. The

12 Oct 2009

INVO Bioscience announce the birth of the first baby conceived by the INVO procedure and INVOcell device

INVO Bioscience, Inc., a medical device company focused on treatment options for patients diagnosed with infertility, announced that on September 29, 2009 the birth of the first baby conceived by the INVO procedure and INVOcell device. The mother is a 40 year old Pakistan woman who had suffered from infertility for 16 years.

9 Oct 2009

HRT may increase urinary incontinence in postmenopausal women

Grappling with the risks and benefits of hormone replacement therapy (HRT) is nothing new for postmenopausal women. Researchers have now added more fuel to the fire, with evidence that HRT could play a role in incontinence.

7 Oct 2009

Strengthening the pelvic floor muscles effective for older women with urinary incontinence

Researchers at Rush University Medical Center have found that a program of pelvic floor muscle exercises, combined with pelvic health education, can be an effective way to manage urinary incontinence in elderly women.

3 Oct 2009

$7.2 million grant awarded to develop microbicide-releasing vaginal ring

The National Institutes of Health has awarded Albert Einstein College of Medicine of Yeshiva University a four-year, $7.2 million grant to develop a microbicide-releasing vaginal ring to prevent HIV transmission.

3 Oct 2009

AMS’ products restore patient's pelvic health and their quality of life

American Medical Systems® (AMS), a leading provider of world-class devices and therapies for both male and female pelvic health, today announced the results of three major clinical studies that each point to a high degree of efficacy and patient satisfaction with AMS’ minimally invasive treatment options for female stress urinary incontinence (SUI) and vaginal prolapse.

30 Sep 2009

Lecture to focus on the increasing need to fund and develop methods of contraception

On October 2nd, 2009, Henry Gabelnick PhD, Executive Director of The CONRAD Program, will give the prestigious Alan F. Guttmacher lecture at the 2009 Association for Reproductive Health Professionals conference being held in Los Angeles, California.

29 Sep 2009

Merck, QIAGEN to collaborate to increase access to HPV vaccination and HPV DNA testing in developing countries

Merck & Co., Inc. and QIAGEN N.V. today announced their intent to collaborate on a new program to increase access to HPV vaccination and HPV DNA testing in some of the most resource-poor areas of the world.

From QIAGEN Manchester Limited 24 Sep 2009

Study on the ranking of obstetrics and gynecology training programs

A ranking of obstetrics and gynecology training programs based on the maternal complication rates of their graduates' patients found these rankings consistent across individual types of complications, suggesting that these rates may reflect measures of overall quality, according to a study in the September 23/30 issue of JAMA, a theme issue on medical education.

23 Sep 2009

New device could be the solution to menstrual pain

While most women experience minor pain during menstruation, for others, the pain can be severe enough to interfere with everyday activities and require medication. New research to be presented at the 2009 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition will reveal initial findings of safety surrounding a new device that may more effectively treat menstrual pain.

22 Sep 2009

Study: Antiretroviral drugs may prevent HIV infection in women

Hopeful that some of the same antiretroviral (ARV) drugs used to treat HIV infection can also prevent it, researchers from the Microbicide Trials Network have enrolled the first participants into a new, large-scale clinical trial testing two approaches of the strategy in women.

17 Sep 2009

VOICE clinical study for testing the efficacy of two HIV prevention strategies

A new, large-scale clinical trial is examining whether antiretroviral medications normally used to treat HIV infection can also prevent HIV infection in women when applied as a vaginal gel or taken as oral tablets once daily.

16 Sep 2009

Breast cancer prevention drugs may negatively affect patients

Three drugs, including tamoxifen, reduce a woman's chance of getting breast cancer, but each drug carries distinct potential harms of its own, according to a new report from HHS' Agency for Healthcare Research and Quality.

16 Sep 2009

Quatrx' second phase 3 study of ospemifene tablets provides positive results

QuatRx Pharmaceuticals Company, a privately-held biopharmaceutical company, today announced positive efficacy results from the second of two patient cohorts in the second pivotal Phase 3 study for Ophena(TM) (ospemifene tablets), the company's investigational compound in development for the treatment of postmenopausal vulvovaginal atrophy (VVA).

10 Sep 2009

Merck's GARDASIL receives approval from FDA Advisory Committee

Merck & Co., Inc. announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee agreed that efficacy, immunogenicity and safety data from clinical trials in males support the use of GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] in boys and men 9 through 26 years of age for the prevention of genital warts caused by human papillomavirus (HPV) types 6 and 11.

10 Sep 2009

Vaginal News and Research

Advisory Committee on Immunization Practices supports the permissive use of GARDASIL

Interim study analysis comparing MENOPUR with rFSH in GnRH Antagonist IVF cycles

No significant differences in pregnancy outcomes with different progesterone formulations

FDA approves Gardasil vaccine usage in boys and men for preventing genital warts

NCCN updates NCCN Clinical Practice Guidelines in Oncology for Cervical Cancer Screening

Overview of procedures and techniques used for embryo transfer under transvaginal ultrasound guidance

INVO Bioscience announce the birth of the first baby conceived by the INVO procedure and INVOcell device

HRT may increase urinary incontinence in postmenopausal women

Strengthening the pelvic floor muscles effective for older women with urinary incontinence

$7.2 million grant awarded to develop microbicide-releasing vaginal ring

AMS’ products restore patient's pelvic health and their quality of life

Lecture to focus on the increasing need to fund and develop methods of contraception

Merck, QIAGEN to collaborate to increase access to HPV vaccination and HPV DNA testing in developing countries

Study on the ranking of obstetrics and gynecology training programs

New device could be the solution to menstrual pain

Study: Antiretroviral drugs may prevent HIV infection in women

VOICE clinical study for testing the efficacy of two HIV prevention strategies

Breast cancer prevention drugs may negatively affect patients

Quatrx' second phase 3 study of ospemifene tablets provides positive results

Merck's GARDASIL receives approval from FDA Advisory Committee

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News